Uncategorized
FDA grants Cellceutix rare pediatric disease designation for Kevetrin to treat retinoblastoma
Cellceutix has received rare pediatric disease designation from the FDA for Kevetrin to treat retinoblastoma, according to a press release.“Receiving the rare pediatric disease designation strengthens our portfolio and adds to our belief that Kevetrin has the potential to provide a meaningful therapeutic benefit to children and families affected by retinoblastoma, where enucleation of the eye is often the only solution,” Leo Ehrlich, CEO of Cellceutix, said in the release.